Search results for "Neoplastic"

showing 10 items of 2901 documents

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

1998

The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single …

MaleCancer Researchmedicine.medical_specialtyAnemiamedicine.medical_treatmentUrologyAntineoplastic AgentsRadiation ToleranceCarboplatinRats Sprague-Dawleychemistry.chemical_compoundHemoglobinsInternal medicinemedicineAnimalsHumansRadiosensitivityErythropoietinEpoetin betaChemotherapybusiness.industryAnemiamedicine.diseaseCarboplatinRecombinant ProteinsRatsRadiation therapyEndocrinologyOncologychemistryErythropoietinToxicitySarcoma ExperimentalbusinessNeoplasm Transplantationmedicine.drugResearch ArticleBritish journal of cancer
researchProduct

Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (A…

1985

The incidence of acute and chronic liver damage and its relation to hepatitis B virus (HBV) infection was evaluated in 164 consecutive children with acute leukemia seen in ten Italian hemato-pediatric units. Thirteen out of 164 children (7.9%) had acute hepatitis (AH) during treatment, while 8/90 (8.8%) showed an acute exacerbation of liver damage within 6 months after therapy withdrawal. Seven of the 13 children with AH while on therapy were HBsAg positive. In 12/13 cases, liver disease progressed to chronicity. Five of eight children who developed AH after completion of treatment were HBsAg positive. Eighty-nine patients (54.2%) developed biochemical evidence of chronic hepatitis during t…

MaleCancer Researchmedicine.medical_specialtyHBsAgChildhood leukemiaExacerbationAdolescentmedicine.disease_causeGastroenterologyacute hepatitisHepatitisLiver diseasechronic hepatitiLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildHepatitis B virusAcute leukemiaHepatitis B Surface AntigensLeukemiabusiness.industryLiver cellacute hepatitichildhood leukemiavirus diseasesInfantmedicine.diseaseacute hepatitis; chronic hepatitis; childhood leukemiaHepatitis BLeukemia LymphoidLeukemiaAcute and chronic hepatitis; childhood leukemia; multicentric study from AIEOPOncologyItalyChild PreschoolPediatrics Perinatology and Child HealthImmunologyAcute DiseaseFemalechronic hepatitisChemical and Drug Induced Liver InjurybusinessMedical and pediatric oncology
researchProduct

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung ca…

2005

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) wer…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsActivities of daily livingHealth StatuscarcinomaVinblastineVinorelbineDeoxycytidineolder peopleQuality of lifeInstrumental activitieCarcinoma Non-Small-Cell LungInternal medicineActivities of Daily LivingAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedAged 80 and overvalidationProportional hazards modelbusiness.industryQLQ-C30Age FactorsCancerVinorelbineclinical trialPrognosismedicine.diseaseGemcitabineComorbidityhumanitiescomorbidityOncologyQuartileQuality of LifePhysical therapyimpactGeriatric oncologyFemalebusinessRandomized-trialmedicine.drug
researchProduct

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.

2000

BACKGROUND The lungs are a frequent site of metastasis in patients with melanoma, and this may cause respiratory problems in the terminal phase of the illness. Inhalation interleukin (IL)-2 therapy to the lung has been piloted and appears to be well tolerated. METHODS Twenty-seven patients were treated with single agent dacarbazine and concurrent high dose inhalation IL-2 36 million IU per day). The patients previously had progressed on chemotherapy, predominately dacarbazine-based regimens. Patients included those with American Joint Committee on Cancer Stage IV melanoma, predominately those with lung metastases, but patients with extrapulmonary metastases also were allowed on the study. R…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDacarbazinemedicine.medical_treatmentAntineoplastic AgentsGastroenterologyMetastasisInternal medicineCause of DeathAdministration InhalationAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntineoplastic Agents AlkylatingMelanomaChemotherapyInhalationbusiness.industryMelanomaRespiratory diseaseRemission InductionCancerReproducibility of ResultsConfounding Factors Epidemiologicmedicine.diseaseRecombinant ProteinsSurgeryDacarbazineTreatment OutcomeOncologyConcomitantDisease ProgressionInterleukin-2FemaleSafetybusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

2017

Leukemia : normal and malignant hemopoiesis 31(4), 846-852 (2017). doi:10.1038/leu.2016.334

MaleCancer Researchmedicine.medical_specialtyLymphomaPopulationMedizinProcarbazineGastroenterologyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorseducationAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overeducation.field_of_studyHematologybusiness.industryRemission InductionPrimary central nervous system lymphomaHematologyLomustinemedicine.diseaseSurgeryTumor BurdenMethotrexateTreatment OutcomeOncology030220 oncology & carcinogenesisCytarabineQuality of LifeMethotrexateRituximabOriginal ArticleFemalebusiness030215 immunologymedicine.drugLeukemia
researchProduct

Are the recommendations of the French consensus conference on the management of colon cancer followed up?

2006

The aim of this study was to determine how the guidelines published after this conference have spread. Pretherapeutic evaluation and treatment were assessed for all colon cancers diagnosed in a well-defined French population in 2000. Patients were classified either as managed according to the recommendations, or as undermanaged or overmanaged. Outside the emergency context, pretherapeutic work-up was classified as in conformity with the consensus in 48.0% of the cases, as undervalued in 21.9% and as overvalued in 30.1%. The resection rate at 90% was not far from the optimum. Pathological data allowed us to classify nearly all cases according to the tumour node metastasis classification; how…

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisHealth Planning GuidelinesEpidemiologyColorectal cancerConsensus Development Conferences as TopicPopulationColonoscopyContext (language use)Antineoplastic AgentsMedicineHumansNeoplasm MetastasiseducationAgedNeoplasm StagingAged 80 and overeducation.field_of_studyTumour node metastasismedicine.diagnostic_testbusiness.industryGeneral surgeryPublic Health Environmental and Occupational HealthConsensus conferenceGuidelineColonoscopymedicine.diseaseSurgeryOncologyColonic NeoplasmsFemaleFranceGuideline AdherencebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck

1992

A group of 60 patients with advanced head/neck cancer were treated with high-dose folinic acid (500 mg/m-2/week-1) plus 5-fluorouracil (400 mg/m-2/week-1 on day 1, and cisplatin (20 mg/m-2/week-1) 24 h after folinic acid infusion was completed. Out of 55 evaluable patients, 10 patients (18%) experienced a complete response with a mean duration of 11.4+ months, 25 patients had a partial response (45%) of 6.7+ months, 6 patients (11%) showed a stabilization of 4.8+ months, and 14 (25%) progressed. The overall response rate was 63.6% (95% confidence limits 56.5%-69.5%). Patients pretreated with radiotherapy had a 67% overall response rate, while those pretreated with chemotherapy showed a 54% …

MaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentCystadenocarcinomaLeucovorinAdenocarcinomaGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisChemotherapyLeukopeniabusiness.industryCarcinomaCancerGeneral MedicineMiddle Agedmedicine.diseaseRadiation therapyOncologyHead and Neck NeoplasmsFluorouracilAnesthesiaCarcinoma Squamous CellVomitingFemaleFluorouracilCisplatinmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal ca…

2011

Abstract Purpose: An efficient adaptive immunity is critical for a longer survival in cancer. We investigated the prognostic value of tumor infiltration by CD8+ T cells expressing the chemokine-receptor-7 (Tccr7) and the correlation between tumor infiltration by Tccr7 and regulatory CD4+FoxP3+ T cells (Treg) in 76 metastatic colorectal cancer (mCRC) patients enrolled in a phase III trial. Experimental Design: Tccr7 and Treg cell infiltration in tumor samples was quantified by immunohistochemistry. The correlation among Tccr7, Treg tumor infiltration, and patients' outcome was evaluated. Results: High Tccr7 tumor infiltration was predictive of prolonged OS [high vs. low Tccr7 score: median 3…

MaleCancer Researchmedicine.medical_specialtyPathologyReceptors CCR7Colorectal cancerCD8 + T cellchemokine-receptor-7medicine.medical_treatmentchemical and pharmacologic phenomenacolorectal cancerKaplan-Meier EstimateAdenocarcinomaCD8-Positive T-LymphocytesGastroenterologyT-Lymphocytes RegulatoryDisease-Free SurvivalLymphocytes Tumor-InfiltratingT-Lymphocyte SubsetsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCytotoxic T cellMedicineHumansAgedProportional Hazards ModelsChemotherapyTumor-infiltrating lymphocytesbusiness.industryFOXP3hemic and immune systemsmedicine.diseasePrognosisImmunohistochemistryTreatment OutcomeOncologyConcomitantFemaletumor infiltrating lymphocytes.businessColorectal NeoplasmsInfiltration (medical)CD8
researchProduct

Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.

1999

Phenylbutyrate (PB) is a potent differentiating agent and currently under investigation for the treatment of prostate cancer (CaP) and other malignancies. We have studied the impact of PB in vitro and in vivo on differentiation, proliferation and apoptosis in the LNCaP and LuCaP 23.1 prostate cancer xenograft models. In vitro we found that i) PB increased PSA secretion/cell, ii) inhibited cell proliferation in a time- and dose-dependent manner resulting in a cell cycle arrest in G1-phase and iii) induced apoptosis at concentrations of 2.5 mM after 3 days of treatment. In PB treated animals tumor growth stabilized or regressed. Combination of castration and PB treatment had a synergistic ant…

MaleCancer Researchmedicine.medical_specialtyProgrammed cell deathTransplantation HeterologousMice NudeAntineoplastic AgentsApoptosisBiologyPhenylbutyrateMiceProstate cancerIn vivoInternal medicineLNCaPTumor Cells CulturedmedicineAnimalsHumansMice Inbred BALB CCell growthCell CycleProstatic NeoplasmsCancerCell Differentiationmedicine.diseasePhenylbutyratesDisease Models AnimalEndocrinologyOncologyCancer cellAndrogensCancer researchCell DivisionNeoplasm TransplantationInternational Journal of Oncology
researchProduct

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

2015

Purpose Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome. Patients and Methods SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Association (LYSA) PRIMA trial of rituximab plus chemotherapy (randomly assigned to rituximab maintenanc…

MaleCancer Researchmedicine.medical_specialtyTime FactorsFollicular lymphomaKaplan-Meier EstimateCHOPGastroenterologyTositumomabDisease-Free SurvivalRisk FactorsTandem Mass SpectrometryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineVitamin D and neurologyHumansProspective StudiesVitamin DProspective cohort studyCyclophosphamideLymphoma FollicularProportional Hazards Modelsbusiness.industryHazard ratioAntibodies MonoclonalORIGINAL REPORTSMiddle Agedmedicine.diseaseVitamin D DeficiencySurgeryTreatment OutcomeOncologyDoxorubicinVincristineCohortDisease ProgressionPrednisoneRituximabFemalebusinessRituximabBiomarkersmedicine.drugChromatography LiquidJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct